Eli Lilly is expanding its cardiovascular disease treatment portfolio by acquiring Verve Therapeutics in a deal valued up to $1.3 billion. Verve's lead gene-editing candidate, VERVE-102, targets PCSK9 to provide a potential one-time therapy for reducing cholesterol and cardiovascular risk. This acquisition follows Lilly’s prior investment and collaboration with Verve, complementing its growing pipeline in genetic medicines. The deal underscores the pharma giant’s commitment to shifting cardiovascular care towards gene editing as a one-and-done treatment approach, ushering in a new era in the management of cardiovascular disease.